Focal positive prostate-specific membrane antigen (PSMA) expression in ganglionic tissues associated with prostate neurovascular bundle: Implications for novel intraoperative PSMA-based fluorescent imaging techniques

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 5, 2013, Pages 572-575

  Chaux, Alcides ^a   Eifler, John ^a   Karram, Sarah ^a   Al Hussain, Turki ^a   Faraj, Sheila ^a   Pomper, Martin ^a   Rodriguez, Ronald ^a   Netto, George J ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Fluorescent imaging technique; Prostate carcinoma; Prostate specific membrane antigen (PSMA); Radical prostatectomy; Radioimmunoscintigraphy; Radiolabeled antibodies

Indexed keywords

PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CYTOPLASM; GANGLION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAOPERATIVE PERIOD; ISOTOPE LABELING; LYMPH VESSEL; MALE; NERVE CELL; NERVE SHEATH; PERIPHERAL NERVE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; STAINING; SURGICAL PATHOLOGY; SURGICAL TECHNIQUE; TISSUE MICROARRAY; TUMOR CELL;

ADENOCARCINOMA; ANTIGENS, SURFACE; CYTOPLASM; FEASIBILITY STUDIES; GANGLION CYSTS; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; INTRAOPERATIVE PERIOD; MALE; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOIMMUNODETECTION; REPRODUCIBILITY OF RESULTS;

EID: 84879462779     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.04.002     Document Type: Article

References (19)

1. Bander N.H. Technology insight: Monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 2006, 3:216-225.
2. Foss C.A., Mease R.C., Fan H., et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: In vivo imaging in experimental models of prostate cancer. Clin Cancer Res 2005, 11:4022-4028.
3. Karam J.A., Mason R.P., Koeneman K.S., et al. Molecular imaging in prostate cancer. J Cell Biochem 2003, 90:473-483.
4. Mhawech-Fauceglia P., Zhang S., Terracciano L., et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: An immunohistochemical study using multiple tumor tissue microarray technique. Histopathology 2007, 50:472-483.
5. Bander N.H., Milowsky M.I., Nanus D.M., et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005, 23:4591-4601.
6. Elsasser-Beile U., Buhler P., Wolf P., et al. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets 2009, 10:118-125.
7. Henry M.D., Wen S., Silva M.D., et al. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res 2004, 64:7995-8001.
8. Olson W.C., Heston W.D., Rajasekaran A.K. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials 2007, 2:182-190.
9. Tagawa S.T., Beltran H., Vallabhajosula S., et al. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 2010, 116:1075-1083.
10. Marchal C., Redondo M., Padilla M., et al. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. Histol Histopathol 2004, 19:715-718.
11. Chang S.S., Reuter V.E., Heston W.D., et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999, 59:3192-3198.
12. Gala J.L., Loric S., Guiot Y., et al. Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: Prognostic value?. Clin Cancer Res 2000, 6:4049-4054.
13. Wang W., Tavora F., Sharma R., et al. PSMA expression in Schwannoma: A potential clinical mimicker of metastatic prostate carcinoma. Urol Oncol 2009, 27:525-528.
14. Kinoshita Y., Kuratsukuri K., Landas S., et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 2006, 30:628-636.
15. Silver D.A., Pellicer I., Fair W.R., et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997, 3:81-85.
16. Campbell M.F., Wein A.J., Kavoussi L.R. Campbell-Walsh Urology 2007, Saunders-Elsevier, Philadelphia, PA.
17. Han M., Partin A.W., Pound C.R., et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001, 28:555-565.
18. Wright J.L., Dalkin B.L., True L.D., et al. Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality. J Urol 2010, 183:2213-2218.
19. Chen Y., Dhara S., Banerjee S.R., et al. A low molecular weight PSMA-based fluorescent imaging agent for cancer. Biochem Biophys Res Commun 2009, 390:624-629.